Understanding the resistance to treatments against breast cancer
Estrogens are responsible for the survival and proliferation of tumor cells in 70 percent of breast cancer cases. Nearly a third of the patients develop a resistance to anti-estrogen treatments such as tamoxifen after a few years. Biologists now reveal how tumor cells become refractory to the drug. They succeeded in identifying eight factors involved in the process of resistance to the treatment. The researchers also suggest various approaches for developing new therapies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 20, 2016 Category: Science Source Type: news
Understanding the resistance to treatments against breast cancer
(Université de Genève) Estrogens are responsible for the survival and proliferation of tumor cells in 70 percent of breast cancer cases. Nearly a third of the patients develop a resistance to anti-estrogen treatments such as tamoxifen after a few years. Biologists reveal how tumor cells become refractory to the drug. They succeeded in identifying eight factors involved in the process of resistance to the treatment. The researchers also suggest various approaches for developing new therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 20, 2016 Category: Cancer & Oncology Source Type: news
Sleep hormone helps breast cancer drug kill more cancer cells
Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects. In a new study, researchers show that the bubbles, called nanostructured lipid carriers (NLCs), made tamoxifen stronger and help it kill cancer cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 14, 2016 Category: Science Source Type: news
Sleep hormone helps breast cancer drug kill more cancer cells
(Elsevier) Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects. In a new study published in Colloids and Surfaces B: Biointerfaces, researchers show that the bubbles, called nanostructured lipid carriers, made tamoxifen stronger and help it kill cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2016 Category: Cancer & Oncology Source Type: news
Atossa Genetics Initiates Additional Drug Development Program
Oral Endoxifen for Patients Refractory to Tamoxifen
SEATTLE, WA--(Healthcare Sales & Marketing Network) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has initiated a new drug development program with oral endoxifen. Endoxifen is an acti... Biopharmaceuticals, OncologyAtossa Genetics, endoxifen, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 7, 2016 Category: Pharmaceuticals Source Type: news
Study may help reassure women taking tamoxifen for breast cancer
A new study may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 6, 2016 Category: Science Source Type: news
Longer Use of Certain Drugs Cuts Recurrence for Breast Cancer Survivors
MONDAY, June 6, 2016 -- Many survivors of breast cancers that are sensitive to estrogen are advised to take hormone-suppressing drugs such as tamoxifen for five years, to cut their odds for a recurrence.
Tamoxifen can have onerous side effects,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 6, 2016 Category: Journals (General) Source Type: news
Ten years of hormone breast cancer drugs 'may benefit some'
Conclusion
This trial suggests that extending the duration of aromatase inhibitor treatment for postmenopausal women to 10 years, rather than five, may reduce the risk of the cancer recurring or new cancer developing in the other breast.
The trial has many strengths, including:
a double-blind design, with neither participants nor the research team aware of allocation to treatment or placebo groups – this is regarded as the gold standard of assessing the effect of an intervention; adherence rates to five years were equivalent in both groups (62% in each), suggesting that participants were unaware of treatment
...
Source: NHS News Feed - June 6, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news
Study may help reassure women taking tamoxifen for breast cancer
(Loyola University Health System) A study presented at ASCO may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 6, 2016 Category: Cancer & Oncology Source Type: news
Extending Estrogen Suppressor May Aid Breast Cancer Patients, Study Says
Women taking a drug known as an aromatase inhibitor for an additional five years lowered the risk of a new or returning cancer, researchers said. (Source: NYT Health)
Source: NYT Health - June 5, 2016 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Breast Cancer Tamoxifen (Drug) American Society of Clinical Oncology Aromatase inhibitor Source Type: news
Could statins prevent breast cancer returning?
Conclusion
The study aimed to identify biological pathways that could be the reason why some ER+ breast cancers relapse after oestrogen-blocking treatment.
It seems that one of the answers for treatment resistance lies in increased activity of cholesterol-producing pathways in the absence of oestrogen. The cholesterol molecules mimic oestrogen and stimulate further tumour growth.
The researchers hope that their research could potentially highlight a new pathway, which could be used as a target for therapeutic treatment in the future. Dr Lesley-Ann Martin from the research team told the media, "This is hugely significa...
Source: NHS News Feed - June 2, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news
Statins 'could be valuable addition to breast cancer treatment'
Research shows some early tumours can produce molecule made from cholesterol which can mimic oestrogenScientists have raised the possibility of using statins – drugs used for reducing cholesterol – to stop some breast cancer tumours returning.The most common form of breast cancer uses oestrogen to grow. Drugs such as tamoxifen and aromatase inhibitors cut off the supply of oestrogen, reducing the chances that the cancer will return after surgery. But about 12,000 of the 40,000 diagnosed oestrogen-receptor positive (ER-positive) cancers still recur every year. Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - May 31, 2016 Category: Science Authors: Sarah Boseley Health editor Tags: Breast cancer Statins Health Science Society UK news Institute of Cancer Research Medical research Source Type: news
tamoxifen, Soltamox, Nolvadex (Discontinued)
Title: tamoxifen, Soltamox, Nolvadex (Discontinued)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/24/2016 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 24, 2016 Category: Cancer & Oncology Source Type: news
Just 2 Years of Tamoxifen Ups Breast Cancer SurvivalJust 2 Years of Tamoxifen Ups Breast Cancer Survival
For premenopausal women with primary breast cancer, taking tamoxifen for only 2 years is better than not taking it at all, according to a Swedish study. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 16, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
AIs Not Tied to Cardiac Ischemia, Stroke in Breast CA PatientsAIs Not Tied to Cardiac Ischemia, Stroke in Breast CA Patients
Breast cancer patients on aromatase inhibitors (AIs) do not seem to be at greater risk for cardiac ischemia or stroke compared with those taking tamoxifen, researchers have found. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
